Advaxis, Inc.

539 articles with Advaxis, Inc.

• Advaxis and Ayala Pharmaceuticals Complete Merger

  1/19/2023

  Advaxis, Inc. (OTCQX: ADXS) today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA).

• Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

  1/12/2023

  Advaxis, Inc. today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center.

• Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

  10/19/2022

  Ayala Pharmaceuticals, Inc. and Advaxis, Inc. announced that they have entered into a definitive merger agreement.

• Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

  10/19/2022

  Ayala Pharmaceuticals, Inc. and Advaxis, Inc. announced that they have entered into a definitive merger agreement.

• 

  Advaxis and Ayala Merge to Hone In on Desmoid Tumors, Prostate Cancer

  10/19/2022

  Advaxis and Ayala Pharmaceuticals entered a reverse merger deal to focus on two clinical-stage cancer therapies: AL102 for desmoid tumors and ADXS-504 for prostate cancer.

• Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

  9/12/2022

  Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the third quarter ended July 31, 2022 and provides a business update.

• Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

  6/29/2022

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update on the Phase 1 clinical study evaluating ADXS-504.

• Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

  6/8/2022

  Advaxis, Inc. (OTCQX: ADXSD), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the second quarter ended April 30, 2022 and provides a business update.

• Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

  6/3/2022

  Advaxis, Inc. announced that it has filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company to implement a one-for-80 reverse split of its issued and outstanding common stock.

• Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the ASCO 2022 Annual Meeting

  5/26/2022

  Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announced the publication of updated results from the clinical trial of the lead asset from its ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program.

• Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

  4/27/2022

  Advaxis, Inc. announced that it will present data from the Phase 2 study of ADXS-503 in combination with pembrolizumab in patients with metastatic non-small cell lung cancer and data from the Phase 1 study of ADXS-504 in patients with biochemically recurrent prostate cancer at the American Society of Clinical Oncology Annual Meeting being held virtually, on June 3-7, 2022.

• Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

  4/8/2022

  Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products announced the publication of results of their KEYNOTE-46 Phase 1/2 open-label, double-arm trial of ADXS-PSA with KEYTRUDA® in patients with metastatic, castration-resistant prostate cancer.

• Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update

  3/17/2022

  Advaxis, Inc. today announces its financial results for the first quarter ended January 31, 2022 and provides a business update.

• Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update

  2/14/2022

  Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announces its financial results for the fiscal year ended October 31, 2021 and provides a business update.

• Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

  1/28/2022

  Advaxis, Inc today announced that the Company entered into an agreement with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock.

• 

  Clinical Catch-Up: January 10-14

  1/17/2022

  Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.

• Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

  1/11/2022

  Advaxis, Inc. today announced updated data from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA®.

• OTC Markets Group Welcomes Advaxis, Inc. to OTCQX

  12/23/2021

  OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, Inc.  (OTCQX: ADXS), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market.

• Advaxis Announces Acceptance for Trading on the OTCQX

  12/22/2021

  Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announced that the Company has satisfied the requirements for trading of the Company’s common stock on the OTCQX® Best Market and will begin trading on OTCQX at the open of the market on December 23, 2021 under the symbol ADXS.

• Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value

  12/17/2021

  Advaxis, Inc. today announced that following the conclusion of its second reconvened special meeting of stockholders on December 16, 2021, it plans to continue to explore additional options to maximize stockholder value.